Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

NCT ID: NCT01484041

Last Updated: 2018-02-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-04-30
• Study Completion Date: 2017-12-31

Brief Summary

This study is for women with confirmed hormone receptor positive HER-2 negative advanced breast cancer with evidence of disease resistance to an aromatase inhibitor.

The purpose of this study is to determine how well these medications work together and/or if they have any side effects in patients with hormone-receptor positive metastatic breast cancer who have demonstrated progression of disease after first line hormonal therapy.

This research is being done to determine if taking an already approved medicine (aromatase inhibitor) in combination with a new medication (dovitinib) results in better outcomes for patients with this disease.

Both dovitinib and an aromatase inhibitor are pills that will be taken at home.

Detailed Description

This is a Phase I/Phase II open-label single arm trial of dovitinib in combination with anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 2.5 mg daily. Study subjects will receive the aromatase inhibitor on which they had previously derived clinical benefit.

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dovitinib plus aromatase inhibitors

Dovitinib with aromatase inhibitor

Group Type: EXPERIMENTAL

Dovitinib

Intervention Type: DRUG

Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest

Aromatase Inhibitors

Intervention Type: DRUG

Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily

Interventions

Dovitinib

Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest

Intervention Type: DRUG

Aromatase Inhibitors

Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily

Intervention Type: DRUG

Other Intervention Names

TKI258; Arimidex; Femara; Aromasin

Eligibility Criteria

Inclusion Criteria

• Female patients with breast cancer either in the primary or metastatic setting
• Tumor must be estrogen receptor and/or progesterone receptor positive and Her-2 negative
• Evidence of disease resistance to an aromatase inhibitor
• ECOG performance status 0 or 1
• Age 18 years or older
• Adequate laboratory values
• Able to give written informed consent
• Measurable disease
• No more than 2 prior chemotherapy regimens in the metastatic setting
• Unlimited prior hormonal therapy in the metastatic setting
• Life expectancy of greater than 3 months
• Post-menopausal
• Tumor must be available for central testing for FGFR1 amplification by FISH/CISH

Exclusion Criteria

• Brain metastases
• Another primary malignancy within 3 years prior to starting drug therapy with the exception of adequately treated in-site carcinoma of the uterine cervix or skin cancer
• Chemotherapy within 3 weeks prior to starting study drug or not recovered from side effects of previous therapy
• Administration of nitrosurea or mitomycin-C within 6 weeks prior to starting study drug or not recovered from side effects of such therapy
• Administration of biologic therapy within 6 weeks prior to starting study drug or not recovered from side effects of such therapy
• Radiotherapy within 4 weeks prior to starting study drug or 2 weeks in the case of localized radiotherapy or not recovered from radiotherapy toxicities
• major surgery, open biopsy or significant traumatic injury within 4 weeks prior to starting study drug or a minor procedure, percutaneous biopsy or placement of a vascular access device within 1 week prior to starting study drug or not recovered from side effects of such procedure or injury
• Chronic concomitant bisphosphonate therapy for the prevention of bone metastases. Bisphosphonate/ denosumab therapy for the management of bone metastases or for the treatment of osteoporosis s allowed.
• Impaired cardiac function or clinically significant cardiac disease
• Impairment of GI function or GI disease that may significantly alter the absorption of dovitinib
• Cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
• Known diagnosis of HIV infection
• Anticoagulation treatment with therapeutic doses of warfarin
• Any concurrent severe and/or uncontrolled concomitant medical condition that could cause unacceptable safety risks or compromise compliance with the protocol
• Pregnant or breast-feeding
• Unwilling or unable to comply with the protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Georgetown University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Claudine Isaacs, MD

Role: PRINCIPAL_INVESTIGATOR

Georgetown University

Locations

Georgetown Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, United States

Countries

United States

Other Identifiers

LCCC 2010-535

Identifier Type: -

Identifier Source: org_study_id